Our integrated research center has signed cooperation agreements with U. of Texas Anderson Cancer Center on breast cancer research, focusing on genetic treatment, proteome, molecular medicine, and stem cells. We have published many valuable articles in recent years.
Avastin (Bevacizumab) has been a popular cancer (including breast cancer) treatment in recent years. However, drugs related to the VEGF approach have serious side effects. To overcome this problem, we have developed a method that combines double-targeted therapy and endo-CD, which has proved more effective and less toxic during the animal test stage.
Cancer stem cells are the most resistant to drugs and are able to regenerate tumors. They are the main barrier to cancer cure. To solve this, we have developed a new gene therapy called BikDD, hoping to effectively eliminate stem cells of breast cancer.
Triple negative breast cancer (negative ER, PR, HER2) accounts for about 15% of all breast cancer cases and so far has no effective treatment. Our newly developed treatment can turn ER (hormone treatment) or HER2 (Herceptin) into positive, so we can treat TNBC with target medicine.
We have also researched into development of new equipment that ensures early diagnosis such as DOS/I image screening system. With such new devices we can increase early detection and design individualized treatments.
Another way of early detection is through ultrasound elastography, finding possible cancer through anomalies in readings from the machine.